These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30537532)

  • 1. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
    Chastain DB; Davis A
    Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.
    Delaportas DJ; Estrada SJ; Darmelio M
    Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
    Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
    PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
    Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
    Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations.
    Bongiovanni M; Thoueille P; Barda B; Mercier T; Marzolini C; Ramponi N; Choong E; Cantù M; Decosterd LA; Bernasconi E
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1503-1504. PubMed ID: 38740656
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.
    García Robles AA; López Briz E; Fraga Fuentes MD; Asensi Diez R; Sierra Sánchez JF
    Farm Hosp; 2018 Mar; 42(2):73-81. PubMed ID: 29501059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oritavancin for acute bacterial skin and skin structure infections.
    Messina JA; Fowler VG; Corey GR
    Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
    Dahesh S; Wong B; Nizet V; Sakoulas G; Tran TT; Aitken SL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
    Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options.
    Purrello SM; Garau J; Giamarellos E; Mazzei T; Pea F; Soriano A; Stefani S
    J Glob Antimicrob Resist; 2016 Dec; 7():178-186. PubMed ID: 27889013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
    Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
    J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.